(Q44437076)

English

Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole

scientific article published on April 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

gastroesophageal reflux disease

0 references

1 reference

10.1023/A:1022812103923

https://api.crossref.org/works/10.1023/A:1022812103923

1 January 2024

author name string

Anne Damiano

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Reshmi Siddique

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Xiao Xu

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

John Johanson

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sheldon Sloan

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12741452

1 January 2024

publication date

1 April 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Digestive Diseases and Sciences

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

48

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

657-662

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

https://scigraph.springernature.com/pub.10.1023/a:1022812103923

0 references

Methodological aspects of evaluation of Quality of Life in upper gastrointestinal diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/12741452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12741452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Healing and relapse of severe peptic esophagitis after treatment with omeprazole

1 reference

https://pubmed.ncbi.nlm.nih.gov/12741452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12741452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gastroesophageal reflux disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/12741452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments

1 reference

https://pubmed.ncbi.nlm.nih.gov/12741452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12741452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Symptoms associated with gastroesophageal reflux disease: development of a questionnaire for use in clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/12741452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS).

1 reference

https://pubmed.ncbi.nlm.nih.gov/12741452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12741452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of gastroesophageal reflux disease on health-related quality of life.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12741452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12741452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1023/A:1022812103923

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44437076&oldid=2042256668"